

Placement to raise \$2.25 million

10 December 2025

Anagenics Limited (ASX:AN1, “Anagenics” or “the Company”) is pleased to announce it has received firm commitments for a two tranche placement of new shares to raise A\$2.25 million in cash before costs (“the Placement”).

Highlights

- Firm commitments received for two tranche placement to raise A\$2.25 million at an issue price of \$0.0046 per share.
- Proceeds will be used to expand existing brands, pursue complementary value-accretive business opportunities, retire debt, working capital, and the costs of the placement.

Anagenics has received firm commitments to raise A\$2.25 million before costs via a placement of a total of approximately 489,130,435 new shares to institutional and sophisticated investors at \$0.0046 per share. The issue price represents an 8% discount to the 5 days Volume Weighted Average Price (VWAP) up to and including Friday 5 December 2025 of \$0.005.

Funds raised under the placement will be used to expand existing brands, pursue complementary value-accretive business opportunities, retire debt, cover day-to-day working capital requirements, and for costs of the placement.

The capital raising will be conducted under two tranches with the first tranche within the Company's existing placement capacity under ASX Listing Rule 7.1 to raise \$342,461 by the issue of 74,448,054 shares, followed by a second tranche to raise \$1,907,539 by the issue of 414,682,381 shares, subject to shareholder approval at a meeting to be held in January 2026.

Participating AFSL holders are entitled to a selling fee of 6% + GST payable in cash on the gross proceeds from the placement and, subject to shareholder approval, the grant of 122,282,609 alignment options with an option exercise price of \$0.008 and expiry date of 3 years after date of grant. The alignment options will be unlisted.

The placement shares will rank equally with existing ordinary shares in the Company.

The **proposed key dates** for the placement are:

Event	Indicative Date
Placement announced and Company resumes trading	Wednesday 10 December 2025
Allotment of Tranche 1 Placement Shares	Monday 22 December 2025
EGM for approval of Tranche 2 Placement Shares	Early February 2026
Allotment of Tranche 2 Placement Shares and alignment options	Early February 2026

For personal use only

This announcement was authorised by the Board of Anagenics Limited.

For further information, please contact:

Sandy Beard
Chair, Anagenics Limited
P: 0412 308 263
E: sandy@xvgroup.com.au

Anagenics Limited (ASX:AN1)

Anagenics is a health, beauty, and wellness business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated anti-aging solutions. BLC Cosmetics Pty Ltd is Anagenics' wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products.

For further information, please see www.anagenics.com

For personal use only